Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04950615 versus placebo in adults with heterozygous familial hypercholesterolemia
NL-OMON40591Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Feb 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia comparing PF-04950615 plus background statin with Placebo plus background statin (2 arms). Started Feb 2014; status: active, not recruiting.
02
Drugs
bococizumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)hypercholesterolemia
Beyond the preview
Go deeper on NL-OMON40591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40591.